+1 862-686-2696
Featured Products
Primary Cells
Immortalized Cell Lines
Stem Cells
Tumor Cell Lines
Transfected Stable Cell Lines
Exosomes
MicroRNA Agomir/Antagomir
Cell Culture Media, Kits & Reagents
Explore Products
Cell
Cell
MicroRNA
MicroRNA
Test and Analysis
Test and Analysis
Primary Cells

Human Acute Lymphoid Leukemia Bone Marrow CD19+ B Cells (Newly Diagnosed/Untreated)

  • For research use only

Cat No.

ABC-TC3001
Product Type

Immune Cells
Cell Type

B Cell
Species

Human
Growth Conditions

37 ℃, 5% CO2
Source Organ

Bone Marrow
Disease

Acute Lymphoid Leukemia
Storage

Liquid Nitrogen

Discover CD19+ B Cells from Acute Lymphoid Leukemia bone marrow for studying disease progression, immunophenotyping, and drug target screening platforms.

Product Image
  • Human Acute Lymphoid Leukemia Bone Marrow CD19+ B Cells (Newly Diagnosed/Untreated)
Get a Quote
Home | Primary Cells | Human Primary Cells | Immune System Primary Cells | Human Acute Lymphoid Leukemia Bone Marrow CD19+ B Cells (Newly Diagnosed/Untreated)

Description

Human Acute Lymphoid Leukemia Bone Marrow CD19+ B Cells are primary B cells isolated from bone marrow of adult patients newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). They retain key characteristics of leukemic B cells and express the CD19 marker, making them suitable for studies of diagnostic criteria for all and evaluation of tumor markers in acute lymphoid leukemia. These cells are valuable for investigating B-cell leukemia biology, drug evaluation, and immunotherapy research, as well as B cell receptor signaling in ALL (acute lymphoblastic leukemia). To ensure the quality of these primary cells, repeated freeze-thaw cycles are not recommended due to the fragile nature of these cells. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.

Product Code

Human Acute Lymphoid Leukemia Bone Marrow CD19+ B Cells (Newly Diagnosed/Untreated), ALL BM CD19+ B cells ND/UT, Human ALL BM CD19+ B cells
Species

Human
Cat.No

ABC-TC3001
Product Category

Primary Cells
Size/Quantity

1 vial
Cell Type

B Cell
Growth Mode

Suspension
Shipping Info

Dry Ice
Growth Conditions

37 ℃, 5% CO2
Source Organ

Bone Marrow
Disease

Acute Lymphoid Leukemia
Biosafety Level

1
Storage

Liquid Nitrogen
Product Type

Immune Cells
Quality Control

All cells test negative for mycoplasma, bacteria, yeast, and fungi.

Application

  • These primary CD19+ blasts enable studies of leukemogenesis, B-cell receptor signaling, drug-resistance mechanisms, and immune evasion. They are widely used for target-validation of CD19-directed immunotherapies, assessment of tyrosine-kinase inhibitors in Ph+ B-ALL, and high-throughput screening of cytotoxic or differentiation-inducing compounds. In general, they are applicable in various experimental setups and commonly serve as useful tools in hematologic and oncology-related research workflows.

Citation

When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).

  • Online Inquiry
  • Product Reviews

Inquiring Human Acute Lymphoid Leukemia Bone Marrow CD19+ B Cells (Newly Diagnosed/Untreated)

We know how valuable your research is to you, but are you wondering what you can expect to pay for quick accurate results every time? Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
High Viability
To succeed in cell culture
Precision and Reliability
To support a consistent result
Customization Options
Tailed to your research

Tags

Let's Advance Life Science Research Together

Contact Us
AcceGen Scroll Top Button